Noopept is a well-known nootropic that is often suggested as a first nootropic. Noopept is over 500 times more potent than Piracetam. Like piracetam, it is capable of enhancing memory, learning, and focus. Noopept is also a powerful antioxidant that prevents neurological disorders and helps the brain grow. Because of this, it is thought to improve long-term memory. The human studies have shown promising results, with potential application in the treatment of Alzheimer's disease.
Noopept (development codes: GVS-111, SGS-111; INN: Omberacetam) is a proline-containing synthetic dipeptide developed by the Russian Academy of Sciences using an original approach based on the imitation of a nonpeptide nootrope (piracetam) structure by means of short-peptide design. It is approved in Russia as a cognition enhancer and differs structurally from classic racetams, belonging to the dipeptide class of nootropics with dual nootropic and neuroprotective effects.
Key Scientific Value & Findings
⚡ Ultra-High Potency — 1000-fold Stronger than Piracetam
Experimental studies show that Noopept exceeds piracetam by 1000 times in effective dose level. In contrast to piracetam facilitating only the early stages of the memory process, Noopept positively influences the memory consolidation and retrieval steps as well. Additionally, Noopept produces an additional selective anxiolytic action.
🛡️ Unique Neuroprotective Mechanism
Noopept demonstrates pronounced neuroprotective effects confirmed both in vivo (in various forms of brain ischemia) and in vitro (on various neuronal models). Its action is based on:
- Antioxidant effect
- Anti-inflammatory action
- Ability to inhibit neurotoxicity of excess calcium and glutamate
- Improvement of blood rheology
🔬 α7 Nicotinic Acetylcholine Receptor-Mediated Modulation
A 2022 study found that Noopept (5 µM) increases action potential firing frequency recorded from GABAergic interneurons in the stratum radiatum of hippocampal CA1 region. This effect was almost completely abolished by α7 nAChR-selective antagonists (α-bungarotoxin and methyllycaconitine), indicating that α7 nAChRs are an important site of action of Noopept.
🧬 HIF-1 Signaling Pathway Activation
Research indicates that Noopept is a moderate activator of the HIF-1 signaling pathway, acting through HIF-1 stabilization, likely by inducing HIF-1α transcription and translation, resulting in increased HIF-dependent gene expression. This mechanism may contribute to its neurotropic activity.
🧠 Alzheimer's Disease Research Potential
- In an Alzheimer's disease model induced by β-amyloid (25-35) injection into Meynert basal nuclei, Noopept (0.5 mg/kg, preventive intraperitoneal injections) completely prevented mnestic disorders.
- Even when treatment was started 15 days after injury (when neurodegenerative changes were still acutely pronounced), Noopept exhibited a significant normalizing effect.
- Mechanisms include: choline-positive effect, multicomponent neuroprotective effect, and stimulation of antibody production to β-amyloid.
💊 Oral Bioavailability Advantage
It was established for the first time that the activity of Noopept is retained both upon parenteral introduction and upon peroral (oral) administration, which is a principal advantage of this proline-containing dipeptide over other, more complex peptides. This property provided a basis for the development of oral formulations.
Frequently Asked Questions
What is Noopept and how does it differ from Piracetam?
Noopept (INN: Omberacetam) is a proline-containing synthetic dipeptide nootropic developed by the Russian Academy of Sciences. Unlike Piracetam, which is a classic racetam, Noopept belongs to the dipeptide class of nootropics and is estimated to be up to 1000 times more potent than Piracetam at effective dose levels. It also positively influences memory consolidation and retrieval — stages that Piracetam does not significantly affect.
What neuroprotective effects does Noopept provide?
Noopept exhibits pronounced neuroprotective effects confirmed both in vivo and in vitro. Its neuroprotective mechanisms include antioxidant activity, anti-inflammatory action, inhibition of neurotoxicity caused by excess calcium and glutamate, and improvement of blood rheology. These properties make it valuable for brain health and neurological protection.
Is Noopept effective for Alzheimer's disease?
Preclinical research shows strong potential. In a β-amyloid-induced Alzheimer's disease model, Noopept at 0.5 mg/kg completely prevented mnestic (memory) disorders. Even when administered 15 days post-injury, it showed significant normalizing effects. Its mechanisms include a choline-positive effect, multicomponent neuroprotection, and stimulation of antibody production against β-amyloid.
Can Noopept be taken orally, or does it require injection?
One of Noopept's key advantages is its oral bioavailability. Research confirmed that its nootropic activity is retained upon both parenteral (injection) and peroral (oral) administration. This distinguishes it from many other complex peptides that lose efficacy when taken orally, and has enabled the development of practical oral formulations.
How does Noopept interact with the HIF-1 signaling pathway?
Noopept has been identified as a moderate activator of the HIF-1 (Hypoxia-Inducible Factor 1) signaling pathway. It acts through HIF-1 stabilization — likely by inducing HIF-1α transcription and translation — resulting in increased HIF-dependent gene expression. This mechanism is thought to contribute to its neurotropic and neuroprotective activities.
What role do α7 nicotinic acetylcholine receptors play in Noopept's effects?
A 2022 study demonstrated that Noopept increases action potential firing frequency in GABAergic interneurons in the hippocampal CA1 region. This effect was nearly abolished by α7 nAChR-selective antagonists such as α-bungarotoxin and methyllycaconitine, confirming that α7 nicotinic acetylcholine receptors are a key site of action for Noopept and play an important role in its cognitive-enhancing effects.
